A double-blind, non-inferiority RCT comparing corifolli during the first seven days of ovarian stimulation using

Human Reproduction

24, 3063-3072

DOI: 10.1093/humrep/dep291

Citation Report

#	Article	IF	Citations
1	The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trialÂ. Human Reproduction, 2010, 25, 995-1004.	0.4	65
2	Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertility and Sterility, 2010, 94, 1922-1924.	0.5	24
3	Dose Selection of Corifollitropin Alfa by Modeling and Simulation in Controlled Ovarian Stimulation. Clinical Pharmacology and Therapeutics, 2010, 88, 79-87.	2.3	38
4	LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles. Reproductive BioMedicine Online, 2010, 20, 565-567.	1.1	22
5	Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reproductive BioMedicine Online, 2010, 21, 66-76.	1.1	91
6	Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online, 2010, 21, 593-601.	1.1	54
7	Corifollitropin Alfa: A Novel Long-Acting Recombinant Follicle-Stimulating Hormone Agonist for Controlled Ovarian Stimulation. Women's Health, 2010, 6, 655-664.	0.7	14
8	GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Human Reproduction Update, 2011, 17, 510-524.	5.2	289
9	Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reproduction, 2011, 26, 2200-2208.	0.4	43
10	Corifollitropin alfa: a new recombinant FSH gonadotropin analog. Expert Review of Obstetrics and Gynecology, 2011, 6, 395-402.	0.4	2
11	Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online, 2011, 22, S23-S31.	1.1	7
12	Corifollitropin Alfa. BioDrugs, 2011, 25, 243-254.	2.2	24
13	Incomplete and inconsistent reporting of maternal and fetal outcomes in infertility treatment trials. Fertility and Sterility, 2011, 95, 2527-2530.	0.5	21
14	No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reproductive BioMedicine Online, 2011, 23, 457-465.	1.1	37
15	Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study. Reproductive BioMedicine Online, 2011, 22, 133-139.	1.1	10
16	Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reproductive BioMedicine Online, 2011, 23, 150-159.	1.1	40
17	No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa. Reproductive BioMedicine Online, 2011, 23, 449-456.	1.1	22
18	What superovulation protocol is best?. , 0, , 67-74.		0

#	Article	IF	Citations
19	The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. International Journal of Women's Health, 2011, 3, 243.	1.1	9
20	New concepts in ovarian stimulation. , 0, , 54-72.		0
21	GnRH antagonists in ART. , 0, , 73-79.		0
22	FSH versus hMG:. , 0, , 75-79.		0
23	Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. European Journal of Pharmacology, 2011, 651, 227-233.	1.7	31
25	GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Human Reproduction, 2011, 26, 2874-2877.	0.4	54
26	Tackling burden in ART: an integrated approach for medical staff. Human Reproduction, 2012, 27, 941-950.	0.4	125
27	Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction, 2012, 27, 2177-2185.	0.4	5
28	A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecological Endocrinology, 2012, 28, 800-804.	0.7	17
29	Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs, and recombinant gonadotropins. , 2012, , 51-74.		0
30	GnRH-antagonists in ovarian stimulation for IVF. , 2012, , 124-130.		2
31	Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries. Human Reproduction, 2012, 27, 1073-1079.	0.4	75
32	Ovarian Stimulation: Today and Tomorrow. Current Pharmaceutical Biotechnology, 2012, 13, 392-397.	0.9	32
34	Ovarian stimulation protocols in assisted reproductive technology: an update. Expert Review of Endocrinology and Metabolism, 2012, 7, 319-330.	1.2	6
35	Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reproductive BioMedicine Online, 2012, 24, 410-419.	1.1	24
36	A randomized assessor-blind trial comparing highly purified hMG andÂrecombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertility and Sterility, 2012, 97, 561-571.	0.5	113
37	Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertility and Sterility, 2012, 97, 876-885.	0.5	44
38	A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertility and Sterility, 2012, 97, 1351-1358.	0.5	21

#	Article	IF	Citations
39	Comment on, â€œIs there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysisâ€. Fertility and Sterility, 2012, 97, e22.	0.5	2
40	Corifollitropin alfa for female infertility. Expert Opinion on Biological Therapy, 2012, 12, 107-112.	1.4	11
41	Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reproductive Biology and Endocrinology, 2012, 10, 32.	1.4	112
42	Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patients. Reproductive Biology and Endocrinology, 2012, 10, 67.	1.4	16
43	Long-acting FSH versus daily FSH for women undergoing assisted reproduction. , 2012, , CD009577.		12
44	Ovulation Stimulation and Cycle Management in IVF. , 2012, , 31-53.		0
45	Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched caseâ€“control study. Gynecological Endocrinology, 2012, 28, 345-350.	0.7	33
46	Gonadotropin stimulation: past, present and future. Reproductive Medicine and Biology, 2012, 11, 11-25.	1.0	19
47	Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial. Reproductive Biology and Endocrinology, 2013, 11, 52.	1.4	7
48	Sperm quality and its relationship to natural and assisted conception: British Fertility Society Guidelines for practice. Human Fertility, 2013, 16, 175-193.	0.7	63
49	IVF endocrinology: the Edwards era. Molecular Human Reproduction, 2013, 19, 799-808.	1.3	14
50	Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Human Reproduction, 2013, 28, 1254-1260.	0.4	38
51	Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertility and Sterility, 2013, 100, 1622-1628.e3.	0.5	116
52	Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin Î±. Reproductive BioMedicine Online, 2013, 26, 253-259.	1.1	31
53	Predictors of ovarian response in women treated with corifollitropin alfa for inÂvitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 2013, 100, 430-437.	0.5	52
54	Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation. Reproductive Biology and Endocrinology, 2013, 11, 90.	1.4	7
58	Is it possible to reduce the incidence of weekend oocyte retrievals in GnRH antagonist protocols?. Reproductive BioMedicine Online, 2013, 26, 50-58.	1.1	13
59	GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. Reproductive BioMedicine Online, 2013, 26, 4-8.	1.1	46

#	Article	IF	Citations
60	Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: anÂobservational pilot study. Fertility and Sterility, 2013, 99, 422-426.	0.5	41
61	Biomarkers of ovarian response: current and future applications. Fertility and Sterility, 2013, 99, 963-969.	0.5	183
62	GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome. International Journal of Endocrinology and Metabolism, 2013, 11, 107-16.	0.3	11
63	Optimal usage of the GnRH antagonists: a review of the literature. Reproductive Biology and Endocrinology, 2013, 11, 20.	1.4	51
64	High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol. Human Reproduction, 2013, 28, 442-452.	0.4	68
65	The Use of Corifollitropin Alfa in Combination with a GnRH Analogue as Final Trigger in the Potential High Responders. Journal of Fertilization in Vitro IVF Worldwide Reproductive Medicine Genetics & Stem Cell Biology, 2014, 03, .	0.2	0
66	Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction, 2014, 29, 1688-1697.	0.4	51
67	Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot study. Human Reproduction, 2014, 29, 1500-1507.	0.4	8
68	Gonadotrophins: The future. Journal of Human Reproductive Sciences, 2014, 7, 236.	0.4	14
69	Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial. Reproductive BioMedicine Online, 2014, 28, 462-468.	1.1	9
70	Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction. Reproductive BioMedicine Online, 2014, 28, 183-190.	1.1	9
71	Medical Approaches to Ovarian Stimulation for Infertility. , 2014, , 701-733.e8.		2
72	Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles. Reproductive Biology and Endocrinology, 2015, 13, 117.	1.4	24
73	Long-acting FSH versus daily FSH for women undergoing assisted reproduction. The Cochrane Library, 2015, , CD009577.	1.5	39
74	Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction. Clinical and Experimental Reproductive Medicine, 2015, 42, 62.	0.5	3
75	Best Practices for Controlled Ovarian Stimulation in In Vitro Fertilization. Seminars in Reproductive Medicine, 2015, 33, 077-082.	0.5	36
76	Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Human Reproduction, 2015, 30, 432-440.	0.4	36
77	Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, caseâ€“control study. Journal of Assisted Reproduction and Genetics, 2015, 32, 429-434.	1.2	4

#	Article	IF	Citations
78	Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. Journal of Ovarian Research, 2015, 8, 33.	1.3	22
79	Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing inÂvitro fertilization. Fertility and Sterility, 2015, 104, 94-103.e1.	0.5	48
80	Biobetter Biologics. , 2015, , 199-217.		5
81	Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation. Reproductive BioMedicine Online, 2015, 31, 339-346.	1.1	13
82	Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. Gynecological Endocrinology, 2015, 31, 885-890.	0.7	21
83	Sub-optimal responders following controlled ovarian stimulation: an overlooked group?. Human Reproduction, 2015, 30, 2005-2008.	0.4	82
85	Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. International Journal of Women's Health, 2016, Volume 8, 609-615.	1.1	7
86	Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation. British Journal of Clinical Pharmacology, 2016, 82, 74-82.	1.1	5
87	Clinical Applications of Gonadotropins in the Male. Progress in Molecular Biology and Translational Science, 2016, 143, 121-174.	0.9	22
88	Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reproductive BioMedicine Online, 2016, 33, 56-60.	1.1	30
89	Efficacy and safety of frozen-thawed embryo transfer in women aged 35 toÂ42Âyears from the PURSUE randomized clinical trial. Fertility and Sterility, 2016, 106, 300-305.e5.	0.5	5
90	Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-MÃ¼llerian hormone. Gynecological Endocrinology, 2016, 32, 625-628.	0.7	4
91	Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Human Reproduction, 2016, 31, 2554-2560.	0.4	43
92	Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-Î² subunit. Human Reproduction, 2016, 31, 169-182.	0.4	15
93	Ovarian Stimulation Protocols. , 2016, , .		6
94	â€˜Modelâ€™ versus â€˜everydayâ€™ patients: can randomized controlled trial data really be applied to the clinic?. Reproductive BioMedicine Online, 2017, 34, 274-279.	1.1	23
96	Effect of progesterone elevation in follicular phase of IVF-cycles on the endometrial receptivity. Reproductive BioMedicine Online, 2017, 34, 422-428.	1.1	56
97	FSH Stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization. Human Reproduction, 2017, 32, 643-652.	0.4	77

#	Article	IF	Citations
98	Corifollitropin alfa compared with follitropin beta in GnRH-antagonist ovarian stimulation protocols in an unselected population undergoing IVF/ICSI. Gynecological Endocrinology, 2017, 33, 968-971.	0.7	2
99	Effect of corifollitropin alfa supplemented with or without LH on ovarian stimulation and embryo viability in rabbit. Theriogenology, 2017, 98, 68-74.	0.9	13
101	El uso de la corifolitropina alfa en donantes de Ã³vulos obtiene la misma eficiencia reproductiva y efectividad que la FSH recombinante, con una mayor comodidad para la donante. Medicina Reproductiva Y EmbriologÃa ClÃnica, 2017, 4, 17-21.	0.1	0
102	Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study. Reproductive BioMedicine Online, 2017, 34, 605-610.	1.1	9
103	Longâ€acting recombinant follicleâ€stimulating hormone in randomâ€start ovarian stimulation protocols for fertility preservation in women with cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 949-953.	1.3	14
104	Ovarian response to 150â€‰Âµg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study. Reproductive BioMedicine Online, 2017, 34, 534-540.	1.1	10
105	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Human Reproduction, 2017, 32, 2225-2233.	0.4	34
106	Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors. Reproductive BioMedicine Online, 2017, 35, 425-431.	1.1	8
107	EstimulaciÃ³n ovÃ¡rica controlada con hormona foliculoestimulante recombinante de acciÃ³n prolongada frente a hormona foliculoestimulante recombinante diaria: experiencia en nuestro centro. Medicina Reproductiva Y EmbriologÃa ClÃnica, 2017, 4, 72-78.	0.1	0
108	An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology, 2017, 15, 17.	1.4	31
109	Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35â€“42 years with a body weight â‰¥50 kg: a randomized controlled trial. Human Reproduction Open, 2017, 2017, hox023.	2.3	5
110	Sequential clomiphene/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study. Journal of Assisted Reproduction and Genetics, 2018, 35, 1047-1052.	1.2	3
111	Cryosurvival of rabbit embryos obtained after superovulation with corifollitropin alfa with or without LH. Animal Reproduction Science, 2018, 192, 321-327.	0.5	5
112	Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study. Reproductive Biomedicine and Society Online, 2018, 5, 46-59.	0.9	10
113	Finding a place for corifollitropin within the PIVET FSH dosing algorithms. Reproductive BioMedicine Online, 2018, 36, 47-58.	1.1	9
114	Preventing Age Related Fertility Loss. , 2018, , .		1
115	Safety of Preventive Oocyte Cryopreservation. , 2018, , 125-139.		0
116	Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients. Journal of the Formosan Medical Association, 2018, 117, 535-540.	0.8	24

#	Article	IF	Citations
117	Are there any differences between antagonist administration on days <6 and â‰¥6 of Controlled Ovarian Hyperstimulation on assisted reproductive technique outcomes?. Journal of the Chinese Medical Association, 2018, 81, 53-57.	0.6	11
118	Association of progesterone production with serum anti-MÃ¼llerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa. PLoS ONE, 2018, 13, e0206111.	1.1	1
119	Gonadotropins and Their Analogs: Current and Potential Clinical Applications. Endocrine Reviews, 2018, 39, 911-937.	8.9	39
120	Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 192-197.	0.5	4
121	Research Methodology and Research Governance in Obstetrics and Gynaecology. , 2018, , 24-37.		0
122	Drugs Used for Controlled Ovarian Stimulation. , 2018, , 9-15.		1
123	Association Between Progesterone Elevation on the Day of Human Chronic Gonadotropin Trigger and Pregnancy Outcomes After Fresh Embryo Transfer in In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles. Frontiers in Endocrinology, 2018, 9, 201.	1.5	26
124	Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF. Human Reproduction, 2018, 33, 1499-1505.	0.4	16
125	Impact of stimulation duration and gonadotropin type on the incidence of premature progesterone elevation â€“ a retrospective analysis of the Ensure data. Gynecological Endocrinology, 2018, 34, 1044-1047.	0.7	4
126	Medical Approaches to Ovarian Stimulation for Infertility. , 2019, , 743-778.e7.		3
127	Use of Corifollitropin Alfa for Ovarian Stimulation: A Retrospective Analysis of 804 Women Undergoing IVF/ICSI. Fertility & Reproduction, 2019, 01, 93-98.	0.0	0
128	Ovulationsinduktion und ovarielle Stimulation. Springer Reference Medizin, 2019, , 1-27.	0.0	0
129	The different impact of stimulation duration on oocyte maturation and pregnancy outcome in fresh cycles with GnRH antagonist protocol in poor responders and normal responders. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 471-476.	0.5	15
130	A single injection of corifollitropin alfa supplemented with human chorionic gonadotropin increases follicular recruitment and transferable embryos in the rabbit. Reproduction in Domestic Animals, 2019, 54, 696-701.	0.6	6
131	Desogestrel versus antagonist injections for LH suppression in oocyte donation cycles: a crossover study. Gynecological Endocrinology, 2019, 35, 878-883.	0.7	3
132	Acceptability and results of Corifollitropin alfa and Desogestrel for ovarian stimulation in oocyte donors. Medicina Reproductiva Y EmbriologÃa ClÃnica, 2019, 6, 1-6.	0.1	0
133	Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study. Gynecological Endocrinology, 2019, 35, 894-898.	0.7	4
134	An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 237, 42-47.	0.5	13

#	Article	IF	Citations
135	State of the art and emerging drug therapies for female infertility. Gynecological Endocrinology, 2019, 35, 835-841.	0.7	9
136	Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders. Frontiers in Endocrinology, 2019, 10, 175.	1.5	10
137	Follicle-Stimulating Hormone. , 2019, , 429-435.		0
138	Corifollitropin alfa for ovarian stimulation in inÂvitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility, 2019, 111, 722-733.	0.5	18
139	Endocrine Control of Reproduction. , 2019, , 40-52.		0
140	Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 232, 101-105.	0.5	5
141	Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?. Reproductive BioMedicine Online, 2019, 38, 1010-1017.	1.1	10
142	A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders. Human Fertility, 2020, 23, 93-100.	0.7	1
143	Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial. Reproductive BioMedicine Online, 2020, 40, 468-474.	1.1	2
144	Discovery of polypeptide ligandâ€receptor pairs based on their coâ€evolution. FASEB Journal, 2020, 34, 8824-8832.	0.2	4
145	SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. Human Reproduction, 2020, 35, 1964-1971.	0.4	15
146	The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment. Diagnostics, 2020, 10, 687.	1.3	12
147	The performance of the ElecsysÂ® anti-MÃ¼llerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reproductive BioMedicine Online, 2020, 41, 29-36.	1.1	7
148	A prospective randomized trial comparing corifollitropin-Î± late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF. Journal of Assisted Reproduction and Genetics, 2020, 37, 1163-1170.	1.2	9
149	Follicle-Stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles. Journal of Clinical Medicine, 2020, 9, 1014.	1.0	61
150	Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI. Reproductive Biomedicine and Society Online, 2020, 10, 28-36.	0.9	3
151	DuoStim cycles potentially boost reproductive outcomes in poor prognosis patients. Gynecological Endocrinology, 2021, 37, 519-522.	0.7	7
152	Type and dose of gonadotropins in poor ovarian responders: does it matter?. Therapeutic Advances in Reproductive Health, 2021, 15, 263349412110242.	1.3	2

#	Article	IF	Citations
153	Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007â€“2017). Reproductive Biology and Endocrinology, 2021, 19, 68.	1.4	18
154	Corifollitropin alpha was not detrimental to follicular ovarian responsiveness measured by follicular output rate (FORT). Human Fertility, 2021, , 1-7.	0.7	0
155	GnRH Antagonist-Based Protocols for In Vitro Fertilization. Methods in Molecular Biology, 2014, 1154, 289-304.	0.4	10
157	Ovulationsinduktion und ovarielle Stimulation. Springer Reference Medizin, 2020, , 115-141.	0.0	1
158	Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. Drugs, 2020, 80, 973-994.	4.9	17
159	How to Improve your ART Success Rates. , 2011, , .		5
160	Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. PLoS ONE, 2016, 11, e0149615.	1.1	73
161	Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials. PLoS ONE, 2016, 11, e0151388.	1.1	36
162	A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders. PLoS ONE, 2016, 11, e0154123.	1.1	20
163	Corifollitropin-Î± compared to daily r-FSH in for patients undergoing intracytoplasmic sperm injection: Clinical trial study. International Journal of Reproductive BioMedicine, 2019, 17, 23.	0.5	2
165	Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol. Jornal Brasileiro De Reproducao Assistida, 2016, 20, 123-6.	0.3	2
166	Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. Jornal Brasileiro De Reproducao Assistida, 2017, 21, 67-69.	0.3	4
167	Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study. Jornal Brasileiro De Reproducao Assistida, 2020, 24, 436-441.	0.3	3
168	Keys of Collaboration to Enhance Efficiency and Impact of Modeling and Simulation. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 131-148.	0.2	0
169	Ovarielle Stimulation. , 2013, , 109-136.		0
171	Clinical aspects of controlled ovarian stimulation with corifollitropin alfa in ART. Russian Journal of Human Reproduction, 2014, , 23.	0.1	1
172	Which Gonadotropin Preparations to Use. , 2015, , 29-38.		0
173	Review on Antagonists. International Journal of Infertility and Fetal Medicine, 2015, 6, 1-10.	0.0	1

#	Article	IF	Citations
174	Human Menopausal Gonadotropin, Pure FSH, and Recombinant FSH: A Comparative Analysis. , 2015, , 83-92.		0
175	Comparative efficacy of the drug corifollitropin-alpha in oocyte donation program. Russian Journal of Human Reproduction, 2015, 21, 58.	0.1	1
176	Long-acting Gonadotropins and Route of Administration. , 2016, , 87-94.		0
177	Corifollitropin alfa. Efficacy, safety and convenience for doctor and patient. Meditsinskiy Sovet, 2016, , 42-49.	0.1	0
178	Treatment Options for Age Related Fertility Loss. , 2018, , 31-42.		0
179	Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles. TâˆšÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2017, 14, 199-202.	0.3	0
180	Professional Development Skills for Obstetricians and Gynaecologists. , 2018, , .		0
181	Corifollitropin alfa for ovarian stimulation in in vitro fertilization in women of advanced maternal age. Russian Journal of Human Reproduction, 2019, 25, 92.	0.1	0
182	Corifollitropin Alfa in Ovarian Stimulation. , 2020, , 97-101.		0
183	Poor responders in in vitro fertilization (IVF) therapy: the challenge continues. Facts, Views & Vision in ObGyn, 2011, 3, 101-8.	0.5	6
184	A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study. Facts, Views & Vision in ObGyn, 2014, 6, 159-65.	0.5	8
185	Corifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF. Facts, Views & Vision in ObGyn, 2015, 7, 223-230.	0.5	0
187	Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol. Scientific Reports, 2021, 11, 22732.	1.6	13
188	Effect of antagonist start day on cycle outcomes in poor responders. Journal of Human Reproductive Sciences, 2021, 14, 400.	0.4	1
189	Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Scientific Reports, 2022, 12, 4456.	1.6	21
190	How to read a Cochrane Review. , 0, , 247-253.		0
191	Endocrine control of reproduction: Controlled ovarian hyperstimulation for ART. , 0, , 19-27.		1
194	Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art. Revista Brasileira De Ginecologia E Obstetricia, 2023, 45, 043-048.	0.3	0

#	Article	IF	Citations
195	Comparing the effects of two different progesterone vaginal gels, Progesonâ„¢ and Crinoneâ„¢, from pharmacokinetics study to clinical applications in patients undergone fresh embryo transfer and frozen-thawed embryo transfer via natural cycle endometrial preparation protocol. Taiwanese Journal of Obstetrics and Gynecology, 2023, 62, 280-285.	0.5	1
196	Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis. CNS Drugs, 2023, 37, 849-866.	2.7	1
198	The GnRH antagonist protocol. , 2024, , 125-138.		0
199	Maximizing fertility outcomes in poor ovarian response patients. , 2024, , 285-294.		0
202	Follicle-Stimulating Hormone. , 2024, , 495-501.		0